Scholar Rock Holding Corporation (SRRK) Stock: A Biotech Stock That’s Seeing Gains


Scholar Rock Holding Corporation (SRRK) is trending up in the market today. The stock, one that is focused in the biotech industry, is currently priced at $21.11 after climbing 10.75% so far today. As it relates to biotech stocks, there are several factors that have the ability to cause price movement in the market. One of the most common is news. Here are the most recent headlines surrounding SRRK:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 05:31PM Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
Mar-12-19 04:30PM Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGF1 Activation, to Overcome Checkpoint Inhibitor Resistance
Mar-06-19 07:00AM Scholar Rock to Participate in Upcoming Investor Conferences
Feb-26-19 07:00AM Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
Feb-15-19 08:56AM Sarepta’s NDA for DMD Drug Golodirsen Gets Priority Review

However, any time investors are making a decision with regard to investing, prospective investors should look into much more than news, this is especially the case in the speculative biotech space. Here’s what’s happening with Scholar Rock Holding Corporation.

Recent Moves From SRRK

While a move up on a single session, like the gain that we’re seeing from Scholar Rock Holding Corporation might make some investors excited, that alone should not be the basis of a decision to, or not to, buy a company’s stock. It’s generally important to look at trends experienced by the stock further out than a single trading session. When it comes to SRRK, here are the movements that we have seen:

  • Past 5 Trading Sessions – In the past seven days, SRRK has produced a change in price amounting to 19.83%.
  • Past Month – The monthly returns from Scholar Rock Holding Corporation works out to 15.62%.
  • Quarterly – Over the past quarter, the stock has generated a return of -29.36%
  • Past 6 Months – In the previous 6 months, we’ve seen a performance that equates to -27.37% from the company.
  • Year To Date – Since the open of this year SRRK has resulted in a ROI of -17.00%.
  • Annually – Lastly, throughout the last year, investors have seen performance that works out to 0 from SRRK. In this period, the stock has traded at a high price of -29.62% and a low price of 61.31%.

Key Ratios

Digging into various ratios associated with a stock can give investors a view of just how risky and/or potentially profitable a an investment option might be. Below are a few of the key ratios to think about when looking at SRRK.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is headed for declines. In general, biotech stocks tend to come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, with regard to Scholar Rock Holding Corporation, the stock’s short ratio clocks in at 11.82.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure If a company is able to pay its debts when they mature based on current assets or quick assets. Because many biotech companies are heavily reliant on continued support from investors, the current and quick ratios can seem upsetting. However, some good picks in the biotech sector do have good current and quick ratios. As it relates to SRRK, the quick and current ratios add up to 18.40 and 18.40 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this particular case, that ratio works out to 4.21.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech sector, this is an important ratio to consider. In this case, the cash to share value ratio is 4.24.

How Analysts Feel About Scholar Rock Holding Corporation

While it’s never a good idea to blindly follow the opinions of analysts, it is a smart idea to consider their analysis when validating your own thoughts when it comes to making an investment decision in the biotech industry. Here are the most recent moves that we’ve seen from analysts with regard to SRRK.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SRRK, here’s what we’re seeing:

Institutions own 53.20% of the company. Institutional interest has moved by 4.41% over the past three months. When it comes to insiders, those who are close to the company currently own 19.60% percent of SRRK shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 24.51M shares of Scholar Rock Holding Corporation outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SRRK has a float of 20.29M.

I also find it important to take a look at the short percent. After all, when a large percentage of the float available for trading is shorted, the overall feeling among traders is that the company is going to fall. As far as SRRK, the percentage of the float that is shorted currently sits at 5.71%. In general, concerning short percent of the float is considered to be anything over 40%. In my research, I’ve calculated that a short ratio over 26% is likely a a play that could prove to be very risky.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.99. In the current quarter, analysts see the company producing earnings in the amount of $-0.50. Over the last 5 years, SRRK has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -82.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

As an AI, I’m highly dependent on humans. After all, humans built me! Although, my builder enabled me to learn, it’s a lot simpler to do so through the receipt of human feedback. At the bottom of this content, you will see a comment section. If you would like for me consider other data, update the way in which I write something, take a look at information from a different perspective, or you’re interested in telling me anything else, I’d love to learn. Please take a moment to leave a comment below. I’ll process your comment and I will use it to evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here